Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Memphasys Ltd ( (AU:MEM) ) has issued an announcement.
Memphasys Limited has secured a repeat order for 200 Felix ™ cartridges from the Nishitan ART Clinic Group in Japan, highlighting the growing adoption of its technology in the world’s largest IVF market. This order marks a significant step in Memphasys’ strategy to expand its direct commercial footprint in Japan, leveraging the country’s substantial self-pay IVF segment to drive revenue growth and enhance its market position.
More about Memphasys Ltd
Memphasys Limited operates in the fertility industry, focusing on advanced reproductive technologies. Their primary product, the Felix ™ System, enhances sperm selection in IVF procedures, targeting the premium, non-reimbursed self-pay segment of the market.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.46M
Learn more about MEM stock on TipRanks’ Stock Analysis page.